Systems approach to therapeutics design

Methods in Molecular Biology

Volumn 500, Issue 1, 2009, Pages 221-236

  Lao, Bert J ^b   Kamei, Daniel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Drug design; Mathematical model; Protein drugs; Trafficking; Transferrin

Indexed keywords

PROTEIN; TRANSFERRIN;

ARTICLE; COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; HELA CELL; HUMAN; METABOLISM; METHODOLOGY; PROTEIN ENGINEERING; PROTEIN TRANSPORT; SYSTEMS BIOLOGY;

COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; PROTEIN ENGINEERING; PROTEIN TRANSPORT; PROTEINS; SYSTEMS BIOLOGY; TRANSFERRIN;

EID: 65649121929     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-525-1_8     Document Type: Article

References (14)

1. Lauffenburger, D. A. and Linderman, J. J. (1993) Receptors. Oxford University Press, New York, NY.
2. Sarkar, C. A., Lowenhaupt, K., Horan, T., Boone, T. C., Tidor, B., and Lauffenburger, D. A. (2002) Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat. Biotechnol. 20, 908-913.
3. Lao, B. J., Tsai, W. L., Mashayekhi, F., Pham, E. A., Mason, A. B., and Kamei, D. T. (2007) Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J. Control. Release 117, 403-412.
4. Rao, B. M., Lauffenburger, D. A., and Wittrup, K. D. (2005) Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol. 23, 191-194.
5. Weaver, M. and Laske, D. W. (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol. 65, 3-13.
6. Hentze, M. W., Muckenthaler, M. U., and Andrews, N. C. (2004) Balancing acts: Molecular control of mammalian iron metabolism. Cell 117, 285-297.
7. Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vasquez, M., and Tsurushita, N. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213-6216.
8. Ciechanover, A., Schwartz, A. L., Dautry-Varsat, A., and Lodish, H. F. (1983) Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J. Biol. Chem. 258, 9681-9689.
9. Yazdi, P. T. and Murphy, R. M. (1994) Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res. 54, 6387-6394.
10. French, A. R. and Lauffenburger, D. A. (1997) Controlling receptor/ligand trafficking: Effects of cellular and molecular properties on endosomal sorting. Ann. Biomed. Eng. 25, 690-707.
11. Kamei, D. T., Lao, B. J., Ricci, M. S., Deshpande, R., Xu, H., Tidor, B., and Lauffenburger, D. A. (2005) Quantitative methods for developing Fc mutants with extended half-lives. Biotechnol. Bioeng. 92, 748-760.
12. Lebron, J. A., Bennett, M. J., Vaughn, D. E., Chirino, A. J., Snow, P. M., Mintier, G. A., Feder, J. N., and Bjorkman, P. J. (1998) Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 93, 111-123.
13. Lippow, S. M., Wittrup, K. D., and Tidor, B. (2007) Computational design of antibodyaffinity improvement beyond in vivo maturation. Nat. Biotechnol. 25, 1171-1176.
14. Halbrooks, P. J., Mason, A. B., Adams, T. E., Briggs, S. K., and Everse, S. J. (2004) The oxalate effect on release of iron from human serum transferrin explained. J. Mol. Biol. 339, 217-226 .